BIOTRONIK is releasing a new line of cardiac resynchronization therapy (CRT) implants, the Ilivia series, that are designed to improve patient response to the therapy and make it customizable for individual needs. The devices are compatible under MRI and feature the company’s MRI AutoDetect capability that automatically switches the devices to a special safe mode during an MRI scan.
A problem with most CRTs is that achieving a more positive reaction from the heart often requires using more energy, thereby depleting the battery inside the implant too quickly and so necessitating extra surgeries. The Ilivia relies on BIOTRONIK’s MultiPole Pacing technology, that reduces energy use, to achieve a better response. It can deliver both sequential or simultaneous pulses, something that can be set and changed to achieve optimal results.
The Ilivia works with a number of leads that can be picked from to match each patient’s anatomy and pacing targets. One of those is the recently announced Sentus QP lead featuring alternative pole-spacing for use on short to medium veins.